ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
ADMA Biologics (Nasdaq: ADMA) will report first quarter 2026 financial results on May 6, 2026 after U.S. market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADMA Biologics (Nasdaq: ADMA) will report first quarter 2026 financial results on May 6, 2026 after U.S. market close. Management will host a live conference call and audio webcast on May 6 at 4:30 p.m. ET.
Participants must register to receive dial-in numbers and a unique PIN; a replay will be archived under Events & Webcasts on the investor website.
Details
News Market Reaction – ADMA
On Apr 29, the day this news came out, ADMA closed 2.75% below the previous close.
Data tracked by StockTitan Argus for the Apr 29 session.
Key Figures
- Earnings release date
- May 6, 2026
- Q1 2026 financial results to be reported after market close
- Conference call time
- 4:30 p.m. ET
- Q1 2026 results and company updates conference call
Previous Earnings date Reports
-
Announced Q4 and FY2025 earnings release date and conference call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for May 6, 2026, at 4:30 p.m. ET
RAMSEY, N.J. and BOCA RATON, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report first quarter 2026 financial results on May 6, 2026, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates.
To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start (although you may dial in at any time during the call). Attendees who will not be asking a question during the call are encouraged to listen in to the live webcast here. An archived replay of the event will be available located under “Events & Webcasts” in the investor section of the Company’s website at https://ir.admabiologics.com/events-webcasts.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com
MEDIA CONTACT:
Longacre Square Partners | ADMABiologics@longacresquare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.